The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
The ED50 of IFNGR1 (Fc Chimera) is typically 0.05-0.1 µg/ml as measured by its ability to neutralize IFN gamma mediated cytotoxicity using the HT-29 colorectal adenocarcinoma cell line.
Concentration information loading...
Shipped at 4°C. Store at +4°C.
Constituents: 10% Trehalose, 1% Human serum albumin
This product is an active protein and may elicit a biological response in vivo, handle with caution.
It is recommended that 0.5 ml of sterile phosphate-buffered saline be added to the vial.
Following reconstitution short-term storage at 4°C is recommended, and longer-term storage of aliquots at -18 to -20°C. Repeated freeze thawing is not recommended.
Antiviral Protein Type II
Antiviral protein, type 2
AVP type II
AVP, type 2
IFN gamma R
IFN gamma R alpha
IFN gamma R1
IFN-gamma receptor 1
Immune interferon receptor 1
Immune interferon receptor for
Interferon gamma receptor 1
Interferon gamma receptor alpha chain
Interferon gamma receptor alpha chain precursor
Receptor for interferon gamma. Two receptors bind one interferon gamma dimer.
Defects in IFNGR1 are a cause of mendelian susceptibility to mycobacterial disease (MSMD) [MIM:209950]; also known as familial disseminated atypical mycobacterial infection. This rare condition confers predisposition to illness caused by moderately virulent mycobacterial species, such as Bacillus Calmette-Guerin (BCG) vaccine and environmental non-tuberculous mycobacteria, and by the more virulent Mycobacterium tuberculosis. Other microorganisms rarely cause severe clinical disease in individuals with susceptibility to mycobacterial infections, with the exception of Salmonella which infects less than 50% of these individuals. The pathogenic mechanism underlying MSMD is the impairment of interferon-gamma mediated immunity whose severity determines the clinical outcome. Some patients die of overwhelming mycobacterial disease with lepromatous-like lesions in early childhood, whereas others develop, later in life, disseminated but curable infections with tuberculoid granulomas. MSMD is a genetically heterogeneous disease with autosomal recessive, autosomal dominant or X-linked inheritance.
Belongs to the type II cytokine receptor family. Contains 2 fibronectin type-III domains. Contains 2 Ig-like C2-type (immunoglobulin-like) domains.
Lane 1 – MW markers; Lane 2 – ab83990; Lane 3 – ab83990 treated with PNGase F to remove potential N-linked glycans; Lane 4 – ab83990 treated with a glycosidase cocktail to remove potential N- and O-linked glycans. 10 μg protein loaded per lane; Coomassie G250 stained. Drop in MW after treatment with PNGase F indicates presence of N-linked glycans. A further drop in MW after treatment with the glycosidase cocktail indicates the presence of O-linked glycans. Additional bands in lane 3 and lane 4 are glycosidase enzymes.
SDS-PAGE - IFN-gamma R1 - Fc Chimera (ab83990)
A sample of ab83990 without carrier protein was reduced and alkylated and focused on a 3-10 IPG strip then run on a 4-20% Tris-HCl 2D gel. Approximately 40 μg of protein was loaded; Gel stained using Deep Purple™. Spot train indicates presence of multiple glycoforms. Spots within the spot train were cut from the gel and identified by protein mass fingerprinting as IFNGR1 (Fc Chimera).
Functional Studies - IFN-gamma R1 - Fc Chimera (ab83990)
Post-translational modifications result in protein heterogeneity. The densitometry scan demonstrates the purified human cell expressed protein exists in multiple glycoforms, which differ according to their level of post-translational modification. The triangle indicates theoretical pI and MW of the protein.
Recombinant human IFNGR1 protein (Fc Chimera) (ab83990) 使用論文
has not yet been referenced specifically in any publications.